Login to myMedcanLocationsCareersEmployee Programs
Memberships
Book an appointment

Now available at Medcan:
The Galleri® multi-cancer early detection test by GRAIL

Book your test today

Medcan is proud to be the official Canadian provider of the Galleri test by GRAIL  

Experience the latest in proactive cancer screening with the Galleri test

The Galleri test by GRAIL sets the standard for multi-cancer early detection and is ideal for those who are seeking a more comprehensive proactive approach to cancer screening. 

Through a single blood draw, this innovative, clinically validated test screens for 50+ cancer types, like pancreatic and ovarian before they become symptomatic, maximizing the opportunity for early diagnosis, when treatment can be most effective.  

When you choose to do this test, Medcan will be with you every step of the way. Our clinical team will guide you through the testing process and help you navigate your results.  

Especially when combined with our Annual Health Assessment, this leading-edge test provides you with one of the most comprehensive approaches to proactive cancer screening available in Canada. 

Complete the Galleri test annually along with routine cancer screenings to support a proactive approach to living well, for life.  

Mike’s story 

Mike received a Cancer Signal Detected (CSD) result with a predicted origin of head and neck through the Galleri test.* This result marked the start of his journey, ultimately leading to a confirmed cancer diagnosis. Now, he wants to share the importance of early detection. 

Screen for multiple cancers with a single blood test 

Cancer treatment is more effective than ever, but we cannot treat what we have not found. And while doctors routinely test for 5 specific cancers today, many cancer deaths in Canada are caused by cancers without recommended screening tests.1 

Currently, single-cancer screenings play an important role in detecting breast, cervical, colorectal, lung, and prostate cancer. These screenings have been shown to decrease cancer-specific mortality for the individual cancers that they detect. However, in Canada the majority of cancers have no recommended screening tests.2 

When cancer is diagnosed early,** before it has time to spread, the overall 5-year cancer-specific survival rate is 4 times higher than when cancer is diagnosed late.3**   

The earlier you detect health issues like cancer, the sooner you can act. Adding the Galleri test to your annual cancer screening plan can increase your chance of finding cancer early. 

How
the
Galleri
Test
Works 

Through a single blood draw, this innovative, clinically validated test screens for 50+ cancer types including pancreatic, bladder, and ovarian, before they become symptomatic. This maximizes the opportunity for early diagnosis, when treatment can be most effective.    

The Galleri test screens for cancer at the time of the blood draw. As cancer can develop at any time, it is recommended that this test be included in your annual screening plan.***  

All cells in your body, including cancer cells, shed DNA fragments into the bloodstream when they complete their life cycle and die. The Galleri test screens your blood sample and identifies DNA fragments shed into the blood by developing cancers. Although there are many types of cancer, these DNA fragments act like a unique “fingerprint” often associated with cancer. 

No cancer signal detected:  

Nearly 99% of people who use the Galleri test will screen negative — which is exactly what you want to hear. Continue with routine cancer screening tests your healthcare provider recommends.  

Cancer signal detected:  

About 1 out of every 100 tests has a Cancer Signal Detected result.4 This means DNA fragments often associated with cancer were found in the blood sample. This result will also include a prediction of the tissue type or organ associated with the cancer signal, called a Cancer Signal Origin. This result is not a cancer diagnosis and requires follow-up diagnostic testing, which may include lab work or imaging ordered by your healthcare provider to confirm cancer. In a clinical study, around 6 out of 10 people with this result were diagnosed with cancer after diagnostic testing.5

Please note that the Galleri test was studied on adults aged 50-79 and the test performance results are based on that population. 

What
to
expect
from
the
testing
process

 Medcan is here to support you every step of the way. 

The Galleri test is not only innovative; it is clinically validated. The test is supported by extensive real-world experience and has been rigorously studied with demonstrated performance in case-controlled and interventional studies of more than 380,000 participants.

7X

Adding the Galleri test to routine cancer screenings can increase your chance of finding cancer by up to 7X.5

73.7%

Galleri’s ability to correctly identify individuals who actually have cancer for 12 of the deadliest cancers.5

The Galleri multi-cancer early detection test

Contact us to connect with a member of our team who can provide more information and answer all of your questions.

$1895

Book your appointment online

Login to myMedcan and book the Galleri multi-cancer early detection test today

Your
Medcan
journey
starts
here

Curious about our services, or ready to start experiencing the benefits of being a Medcan client?

Disclaimers and Resources:

*The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. 1 in 100 can expect to receive a CSD result, and approximately 60% of these individuals will receive a confirmed cancer diagnosis. The overall sensitivity in study participants with head and neck cancer was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV). 

**“Early/Localized” includes invasive localized tumors that have not spread beyond the organ of origin; “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body. 

***Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test is not a genetic risk assessment and does not predict future genetic risk for cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false/negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests.

Important Safety Information: The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. 

Lab / Test information: The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. This test is not Health Canada or FDA approved, and has not been endorsed by any professional medical societies at this time. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.  

1 Extrapolated from cancer death rates available at https://cancer.ca/en/research/cancer-statistics/cancer-statistics-at-a-glance [cited on Oct 14, 2025]

2 SEER Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006-2015. GRAIL Ddata on file GA-2021-0065 

3 American Association for Cancer Research. Cancer progress report 2023. https://cancerprogressreport.aacr.org/progress/ 

4 Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi: 10.1016/S0140-6736(23)01700-2  

5 Nabavizadeh N, McDonnell C, Kurbegov D, et al. Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended-Use Population: Initial Results from the Registrational PATHFINDER 2 Study. ESMO 2025. Presentation LBA64.